University Hospital Virgen Macarena
Clinical and molecular epidemiology, risk factors, and therapy of infections due to multi-drug resistant organisms and successful clones. Improving clinical management and antimicrobial therapy of bloodstream infections. Control of multidrug-resistant bacteria. Genetic and epidemiologic bases for betalactams and fluoroquinolone resistance in gram negatives. Improving antibiotic use and development of computerized tools to aid prescribing. Molecular basis of biofilm formation. Contributions. Betalactam/betalactamase inhibitors are efficacious in the treatment of bacteraemia due to ESBL-producing E. coli (ESBLEC) (Rodríguez-Baño et a, Clin Infect Dis 2012). Oral fosfomycin and amoxicillin/clavulanic acid are useful in cystitis due to ESBLEC (Rodríguez-Baño et al, Arch Intern Med 2008). Identification of risk factors for bacteraemia due to ESBLEC (Rodríguez-Baño et al, Clin Infect Dis 2010 and J Clin Microbiol 2010) for the identification of patients who would need specific empirical therapy. Usefulness of an infection control bundle for the control of multidrug-resistant bacteria (Rodríguez-Baño et al, Am J Infect Control and Infect Control Hosp Epidemiol 2010. Velasco et al, J Hosp Infect 2009. Conejo et al, J Antimicrob Chemother 2010). Registered device to investigate the dynamic activity of antimicrobials against biofilm-producing organisms (see below).
International publications: 97 (9 articles in D1 and 58 in Q1).
Publications in collaboration with other groups from REIPI: 63.
Cumulative Impact Factor: 361,213.
Grants: 33 grants with competitive funding: 1.627.632 €.
International grants: 1
National grants: 20 and regional: 12.21 of them have a Principal Investigator (Head Researcher) member of the group. 12 in collaboration with other groups from REIPI. Guidelines published in PubMed: 7 (3 national and 4 international).
Patent: Device and Method designed for the dynamic study of biofilms formed on catheters (ES2354781).
Independent Clinical Trials: 1 as Head Researcher and 4 in collaboration with other REIPI groups.
Epidemiologic studies: 14 (10 as Head Researcher of the group and 4 collaborating with another group of REIPI).
Dr. Jesús Rodríguez Baño